The global catheter-related bloodstream infection (CRBSI) treatment market size was valued at USD 1,466.9 million in 2022. It is expected to reach USD 2,668.6 million by 2033. The catheter-related bloodstream infection (CRBSI) treatment market is slated to reach USD 1,541.3 million by 2023.
The global catheter-related bloodstream infection (CRBSI) treatment market is anticipated to witness a considerable CAGR of 5.6% in the review period 2023 to 2033. The market for CRBSI in South Asia reached a valuation of USD 469.9 million in 2022.
Latest Catheter-related Bloodstream Infection (CRBSI) Treatment Market Trends-
| Attributes | Key Insights |
|---|---|
| Catheter-related Bloodstream Infection (CRBSI) Treatment Market Estimated Size (2023E) | USD 1,541.3 million |
| Catheter-related Bloodstream Infection (CRBSI) Treatment Market Projected Valuation (2033F) | USD 2,668.6 million |
| Value-based Catheter-related Bloodstream Infection (CRBSI) Treatment Market CAGR (2023 to 2033) | 5.6% |
| Collective Value Share: Top 5 Countries (2022) | 59.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing CRBSI Prevalence Worldwide
The prevalence of catheter-related bloodstream infections (CRBSI) is a persistent and pressing concern across healthcare settings. This concern is particularly pronounced in healthcare facilities, where invasive procedures and the utilization of catheters are commonplace. As these infections continue to exert their impact, patients demand effective treatment solutions in this landscape.
The demand for treatments tailored to combat CRBSI is expected to surge in tandem with their prevalence. Innovations in medical technology are set to contribute to reducing the incidence of these infections.
Innovations in CRBSI Treatment
These innovations include ongoing advancements in catheter design, materials, and infection-resistant coatings. Research efforts to understand the underlying causes of CRBSI and develop novel treatment strategies are also underway, promising more targeted and potent interventions.
Infection Control and Transformative Focus
The intensifying focus on infection control across healthcare facilities and organizations is projected to ignite a transformative wave. It is expected to render patient safety and the mitigation of healthcare-associated infections (HAIs) as paramount objectives.
The emotional emphasis on infection prevention can also create a significant ripple effect that drives investments in catheter-related bloodstream infections (CRBSI) treatments. This is consequently anticipated to propel the CRBSI treatment demand.
Multifaceted Approach to Infection Control
The heightened focus on infection control is set to encompass a multifaceted approach. Rigorous adherence to hand hygiene protocols and meticulous environmental cleaning are expected to be integral to this strategy. This is also projected to include proper utilization and maintenance of medical devices, such as catheters.
Evidence-based guidelines and best practices are continuously evolving. It is further expected to compel healthcare organizations to embrace the latest advancements in infection prevention to bolster patient safety and care quality.
CRBSI Treatment Investments
Investments in CRBSI treatments are expected to be influenced by several factors. Institutions must demonstrate their commitment to patient safety as healthcare-associated infections garner public attention and scrutiny. To do so, they will likely adopt state-of-the-art solutions that can effectively combat CRBSI.
Financial implications of HAIs are substantial. It is projected to prompt healthcare administrators to invest in prevention strategies that can ultimately reduce costs associated with extended hospital stays and additional treatments. Rising focus on infection control in healthcare facilities is set to resonate as a powerful catalyst driving the catheter-related bloodstream infections (CRBSI) treatment market.
Research and Development Investments
Considerable research & development investments by pharmaceutical and medical device companies herald a new era in treating and preventing CRBSIs. These investments signify a collective determination to pioneer novel treatment modalities and innovative catheter technologies. These are expected to prioritize patient safety and elevate infection prevention strategies.
Commitment to a Bright Future
As the healthcare landscape evolves, the unwavering commitment to research & development underscores a shared aspiration to forge a bright future. This is expected to push the efficient management of CRBSIs, enhance patient outcomes, and expand healthcare innovations.
Infectious diseases have historically been met with an evolving arsenal of therapeutic options. Antibiotics, antivirals, and antifungal medications have transformed the landscape of infectious disease management. However, the CRBSI treatment market paints a different picture.
The inherent complexities of catheter-related infections are set to render the development of effective treatments. It can be intertwined with the use of medical devices that inadvertently facilitate pathogen entry.
The formation of biofilms on catheter surfaces is expected to further compound the challenge. These biofilms act as protective fortresses, harboring bacteria and impeding the penetration of antibiotics.
The unique characteristics of CRBSI demand innovative approaches that can breach these protective barriers and target infections at their source. Yet, the limited options available are expected to hinder healthcare professionals' ability to choose therapies that effectively counteract biofilm-associated infections.
Limited treatment options available in the CRBSI treatment market are projected to impose a substantial restraint on the fight against catheter-related infections. This scarcity of therapeutic choices, compounded by biofilm complexities and antimicrobial resistance, can hamper the work of healthcare professionals as they endeavor to manage CRBSIS effectively.
Antimicrobial resistance stands as a towering obstacle in the catheter-related bloodstream infection (CRBSI) treatment market. It will likely cast a shadow of urgency and complexity over efforts to effectively manage and combat these infections.
The escalating prevalence of antimicrobial-resistant bacteria has further morphed into a critical challenge, directly impacting the landscape of the CRBSI treatment market. This mounting resistance is projected to threaten to erode the efficacy of existing antibiotics. It is not only expected to diminish the range of available treatment options but also necessitate intricate maneuvers to develop novel therapies in the face of an evolving microbial adversary.
In the CRBSI treatment market, the challenge posed by antimicrobial resistance is two-fold. The effectiveness of established antibiotics, which have historically been the mainstay of infectious disease management, is compromised.
Pathogens that have developed resistance can continue to proliferate and thrive in the bloodstream. This can further lead to prolonged infections, increased morbidity, and elevated mortality rates among the affected patients. Increasing prevalence of antimicrobial-resistant bacteria is set to cast a daunting shadow over the CRBSI treatment market.
Principal Consultant
The global catheter-related bloodstream infection (CRBSI) treatment market exhibited a steady CAGR of around 4.2% during the historical period from 2018 to 2022. It stood at USD 1,466.9 million in 2022. The market for Catheter-related bloodstream infection (CRBSI) treatment is anticipated to register a CAGR of 5.6% in the forecast period.
| Historical Catheter-related Bloodstream Infection (CRBSI) Treatment Market Value (2022) | USD 1,466.9 million |
|---|---|
| Historical Value-based Catheter-related Bloodstream Infection (CRBSI) Treatment Market CAGR (2018 to 2022) | 4.2% |
Antimicrobial resistance is expected to pose a formidable threat to modern medicine. The indiscriminate use of antibiotics and other antimicrobial agents has significantly fueled this crisis from 2018 to 2022.
Acknowledging this critical concern, the approach to CRBSI treatment is evolving to balance the necessity of eradicating infections. This includes the imperative to preserve the efficacy of antimicrobials for future generations.
Adopting a holistic approach encompassing infection prevention and control measures alongside antimicrobial stewardship is vital. Stringent infection control protocols, proper catheter care, and reduced unnecessary catheter usage can lower the burden of CRBSIs. These factors are expected to minimize the need for extensive antimicrobial treatment.
The trend toward more judicious use of antimicrobial agents in CRBSI treatment is projected to reflect a pivotal moment in the fight against antimicrobial resistance. In the catheter-related bloodstream infection (CRBSI) treatment market, the utilization of antifungal agents is set to be a key component.
It is expected to be often governed by clinical guidelines in addressing the complex issue of hospital infections, particularly those associated with catheter use. The rising challenge of antibiotic resistance is projected to accentuate the need for innovative solutions. This is further anticipated to make developing and deploying practical clinical guidelines imperative.
In such a context, preventing and managing CRBSIs requires a multifaceted approach, including robust infection control measures and the judicious use of antibiotics & antifungal agents. These are all aimed at enhancing patient outcomes and reducing the burden of hospital-acquired infections.
Catheter-related bloodstream infection (CRBSI) represents a critical subset of healthcare-associated infections, often necessitating antibiotic treatment. These infections are set to be directly linked to the presence of catheters in medical settings. These are projected to emphasize the importance of infection prevention measures.
Innovations such as antimicrobial-coated catheters are expected to reduce the risk of bacterial and fungal infections. The pharmaceutical industry will likely play a pivotal role in developing antibiotics and antifungal agents essential for CRBSI treatment.
On the other hand, patient safety and infection prevention protocols remain paramount. These are anticipated to align with the broader goals of enhancing medical device safety and infectious disease management in the healthcare system.
In the table below of the growth potential of the catheter-related bloodstream infection (CRBSI) treatment market, CAGRs of the top 5 countries are provided. Out of the 5, India is likely to lead the catheter-related bloodstream infection (CRBSI) treatment market by exhibiting a CAGR of 7.2% from 2023 to 2033. China and Indonesia are expected to witness catheter-related bloodstream infection (CRBSI) treatment demand at the same CAGR of 6.6%.
Catheter-related Bloodstream Infection (CRBSI) Treatment Market Growth Outlook by Key Countries
| Country | Value-based CAGR |
|---|---|
| United States | 4.4% |
| India | 7.2% |
| China | 6.6% |
| Japan | 5.7% |
| Indonesia | 6.6% |
The United States catheter-related bloodstream infection market is anticipated to witness a 4.4% CAGR from 2023 to 2033. The country’s catheter-related bloodstream infection (CRBSI) treatment market size 2022 was USD 233.9 million.
The United States has a significant incidence of CRBSIs due to the extensive use of catheters in healthcare settings. This high incidence is anticipated to drive the demand for CRBSI treatment drugs.
HAIs, including CRBSIs, have been a leading concern in the United States. Healthcare facilities and regulatory bodies have prioritized infection control. It is expected to lead to growing investments in prevention and treatment strategies.
As per the Centers for Disease Control and Prevention (CDC), healthcare in the United States is now safer than it was ten years ago due to the enormous advancements made toward the shared objective of eliminating HAIs. It is expected to be crucial to build on this achievement and keep working toward the eradication of HAIs.
In the review period, India is expected to showcase a CAGR of around 7.2% in the catheter-related bloodstream infection (CRBSI) treatment market. The country is projected to reach a valuation of USD 492.6 million by 2033.
India has one of the most prominent populations globally. This means a substantial patient pool can require CRBSI treatment. The sheer volume of patients is expected to drive demand for CRBSI-related products and services.
India also has a growing healthcare infrastructure, with an increasing number of hospitals, clinics, and healthcare facilities. This infrastructure is set to create new opportunities for the diagnosis and treatment of CRBSIs and the growth of infection control measures.
According to the India Brand Equity Foundation (IBEF), the healthcare sector in the country is anticipated to surge by three times, at a CAGR of 22% from 2016 to 2022, from USD 110 billion to USD 372 billion. The healthcare infrastructure in India is anticipated to cost USD 349.1 billion by FY22.
China is estimated to record a steady CAGR of 6.6% in the review period. The country will likely reach USD 422.8 million by 2033 in the catheter-related bloodstream infection (CRBSI) treatment market.
China has invested heavily in expanding its healthcare infrastructure by constructing new hospitals, clinics, and healthcare facilities. This expansion strategy is projected to help improve access to healthcare services, including CRBSI diagnosis and treatment.
China also has a rapidly growing pharmaceutical industry that produces many products, including antibiotics and antimicrobial agents used in CRBSI treatment. Pharmaceutical companies in the country are projected to invest in research & development activities through 2033.
The Shanghai Jiao Tong University School of Medicine conducted a study in June 2022 about the incidence rate and economic burden of CRBSI. The investigation was conducted in several ICUs across three tertiary-level hospitals connected to Shanghai Jiao Tong University, totaling 2300 beds. The Department of Infection Control regularly monitored for CRBSI in ten separate ICUs.
Hematology ICU had the most prominent incidence rate of CRBSI at 4.43 per 1000 CVC days. About 51 patients were matched correctly with controls. The annual expenditure in the CRBSI group was USD 67,923, which was substantially more than that in the controlling group (P 0.001). CRBSI was responsible for the average cost of USD 33,227.
Japan’s central line-associated bloodstream infection (CLABSI) treatment market is projected to record a CAGR of 5.7% from 2023 to 2033. It is anticipated to reach a valuation of USD 230.1 million by 2033 in the catheter-related bloodstream infection (CRBSI) treatment market.
Rising demand for micro-guide catheters in Japan is anticipated to drive the catheter-related bloodstream infection (CRBSI) treatment market through 2033. Increasing use of these catheters in interventional cardiology, radiology, and other medical procedures is expected to aid demand.
Ongoing advancements in diagnostics and minimally invasive procedures are also projected to push the adoption of micro-guide catheters in Japan. With the rising use of these catheters, the prevalence of CRBSIs is also set to surge, thereby pushing the demand for effective treatment options.
Growing use of micro-guide catheters in intricate medical interventions is another vital factor projected to support growth in Japan. Underlying health conditions and compromised immune systems of patients undergoing these procedures can also propel them toward susceptibility to infections such as CRBSIs. This is expected to drive the demand for advanced CRBSI treatment options to ensure patient care and safety.
Indonesia is expected to reach a valuation of USD 135.4 million by 2033 in the intravascular catheter-related infection treatment industry. During the forecast period, it is estimated to witness a CAGR of 6.6% in the catheter-related bloodstream infection (CRBSI) treatment market.
Surging focus of healthcare professionals on infection control is expected to drive early detection and enhanced surveillance of CRBSIs in Indonesia. Several healthcare facilities are estimated to deploy cutting-edge monitoring systems to efficiently detect infections. Rising vigilance is expected to push the demand for CRBSI treatment options for managing complex cases once diagnosed.
Multiple healthcare companies in Indonesia are set to prioritize patient safety. CRBSIs are anticipated to be a crucial concern. Rising emphasis on patient safety and well-being is further set to push the need for CRBSI treatment options. This is attributed to the urgent need to ensure positive patient outcomes and lower infection risks.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below highlights the global drug class growth of the catheter-related bloodstream infection market. Under drug class, the echinocandin segment will likely remain dominant in the assessment period.
The echinocandin segment, while smaller, is set to showcase a significant CAGR of 6.8% through 2033 in the catheter-related bloodstream infection (CRBSI) treatment market. It is expected to be followed by teicoplanin, vancomycin, daptomycin, cloxacillin, cefazoline, and ceftazidime segments.
Catheter-related Bloodstream Infection (CRBSI) Treatment Market Growth Outlook by Drug Class
| Drug Class | Value-based CAGR |
|---|---|
| Cloxacillin | 5.8% |
| Ceftazidime | 4.5% |
| Cefazoline | 4.9% |
| Daptomycin | 5.9% |
| Vancomycin | 6.2% |
| Teicoplanin | 6.3% |
| Echinocandin | 6.8% |
| Others | 4.7% |
By drug class, the echinocandin segment will likely showcase a 6.8% CAGR in the forecast period in the catheter-related bloodstream infection (CRBSI) treatment market. As echinocandins are known for having antifungal solid effects when used with Candida species, they are expected to witness a surging demand globally. With the increasing development of the Candida species during CRBSIs, echinocandin is set to be ideal for combating fungal infections, especially those brought on by catheters.
Echinocandins are also expected to show a wide range of anti-Candida strain activity. It can include activities against those strains that have evolved sensitivity to different antifungal medications. Their versatility in targeting several fungal species is projected to raise their effectiveness in CRBSI scenarios when a particular microbial infection cannot be detected.
Echinocandins are also estimated to have a relatively low resistance rate compared to other antifungal classes. This feature is expected to help healthcare professionals use it to treat CRBSIs, where antimicrobial resistance can pose a significant challenge. Hence, their low risk of resistance development will likely contribute to their high demand.
The table below highlights the global CRBSI treatment market demand analysis by distribution channel. Under the drug class, the online pharmacies segment will likely remain dominant in the assessment period.
The online pharmacies segment, while smaller, is set to showcase a significant CAGR of 6.6% through 2033 in the catheter-related bloodstream infection (CRBSI) treatment market. Hospital pharmacies, retail pharmacies, and drug store segments are expected to follow it.
Catheter-related Bloodstream Infection (CRBSI) Treatment Market Growth Outlook by Distribution Channel
| Distribution Channel | Value-based CAGR |
|---|---|
| Hospital Pharmacies | 5.3% |
| Retail Pharmacies | 5.6% |
| Drug Store | 5.9% |
| Online Pharmacies | 6.6% |
In terms of distribution channels, the online pharmacies segment is projected to register a CAGR of 6.6% through 2033 in the catheter-related bloodstream infection (CRBSI) treatment market. Online pharmacies are expected to give customers the convenience of always being reachable. Without physically visiting pharmacies or medical institutions, healthcare professionals and patients can get choices, order, and browse for CRBSI treatment at their convenience.
A wider variety of CRBSI treatment options, including multiple brands and formulas, are set to be frequently offered by online pharmacies. These are anticipated to allow for investigation of other possibilities, evaluation of costs, and selection of the suitable course of action for their unique requirements.
Online CRBSI treatment purchases are also expected to provide patients with a degree of privacy and secrecy that can be significant to them. Without the potential difficulty or embarrassment of addressing delicate medical situations in person, they are projected to receive the essential drugs covertly. These aforementioned advantages of online pharmacies are estimated to bolster their demand worldwide.
Drug manufacturers continuously focus on developing drug molecules that can target multiple indications. Several cutting-edge innovations are underway that can drastically reduce healthcare costs and the length of stay. Several prominent companies in the catheter-related bloodstream infection (CRBSI) treatment market are adopting strategies such as mergers & acquisitions, new product launches, patent generation, research activities, and collaborations.
For instance,
| Attribute | Details |
|---|---|
| Estimated Catheter-related Bloodstream Infection (CRBSI) Treatment Market Size (2023) | USD 1,541.3 million |
| Projected Catheter-related Bloodstream Infection (CRBSI) Treatment Market Valuation (2033) | USD 2,668.6 million |
| Value-based Catheter-related Bloodstream Infection (CRBSI) Treatment Market CAGR (2023 to 2033) | 5.6% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | Value (USD million) |
| Key Regions Covered in Catheter-related Bloodstream Infection (CRBSI) Treatment Market | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa |
| Key Countries Covered in Catheter-related Bloodstream Infection (CRBSI) Treatment Market | United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Segments Covered in Catheter-related Bloodstream Infection (CRBSI) Treatment Market | Drug Class, Route of Administration, Indication, Distribution Channel, and Region |
| Key Companies Profiled in Catheter-related Bloodstream Infection (CRBSI) Treatment Market |
Aurobindo Pharma Limited; B. Braun Medical Inc.; Eli Lilly and Company; Fresenius SE & Co. KGaA; GSK plc; Merck & Co., Inc.; Mylan N.V. (Viatris); Novartis; Pfizer Inc.; Sanofi AG; SteriMax Inc.; Teva Pharmaceutical Industries Ltd.; |
The market is set to reach USD 2,668.6 million by 2033.
The CRBSI treatment market is expected to witness a 5.6% CAGR from 2023 to 2033.
The echinocandin segment will likely showcase a 6.8% CAGR in the forecast period.
The development of innovative catheter designs and infection-resistant technologies is the latest trend.
Novartis, GSK plc, and Pfizer Inc. are the leading providers.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value-Added Insights 5. Market Background 6. Global Market Demand (in Value or Size in USD million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 7.1. Cloxacillin 7.2. Ceftazidime 7.3. Cefazoline 7.4. Daptomycin 7.5. Vancomycin 7.6. Teicoplanin 7.7. Echinocandin 7.8. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 8.1. Oral 8.2. Injectable 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 9.1. Bacterial Infections 9.2. Fungal Infection 9.3. Viral and Parasitic Infections 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Hospital Pharmacies 10.2. Retail Pharmacies 10.3. Drug Store 10.4. Online Pharmacies 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. South Asia 11.5. East Asia 11.6. Oceania 11.7. Middle East & Africa 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 19. Market Structure Analysis 20. Competition Analysis 20.1. Baxter International 20.2. Aurobindo Pharma Limited 20.3. B. Braun Medical Inc. 20.4. Eli Lilly and Company 20.5. Fresenius SE & Co. KGaA 20.6. GSK plc 20.7. Merck & Co., Inc. 20.8. Mylan N.V. (Viatris) 20.9. Novartis 20.10. Pfizer Inc. 20.11. Sanofi AG 20.12. SteriMax Inc. 20.13. Teva Pharmaceutical Industries Ltd. 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
CRBSI Treatment Market
